Private Equity, VC & Investor
Atomico vs Vitruvian Partners
Structured technology and market comparison · 2026
Direct Feature Comparison
Atomico · vs · Vitruvian PartnersVenture capital firm investing in technology startups and growth companies.
Private equity firm backing higher-growth companies across Europe and the US.
Analyze all overlapping signals and tech stacks for Atomico and Vitruvian Partners
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Atomico and Vitruvian Partners?
When comparing Atomico and Vitruvian Partners, both platforms operate within the Private Equity, VC & Investor ecosystem. Atomico is positioned as Venture capital firm investing in technology startups and growth companies, whereas Vitruvian Partners focuses on Private equity firm backing higher-growth companies across Europe and the US. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Atomico and Vitruvian Partners?
When evaluating Atomico and Vitruvian Partners, enterprise buyers also consider other platforms in Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Atomico and Vitruvian Partners compare?
Atomico is headquartered in GB (founded in 2006) with 50–200 employees. Vitruvian Partners is based in GB (founded in 2006) with 50–200 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Atomico vs Vitruvian Partners
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Atomico
Recent Signals
- ·Tech.eu (European Tech & Deals)Venture Capital
UK Launches Refugee Venture Fund with £300K Initial Capital
The Refugee Venture Fund (RVF) launched in the UK with an initial £300,000, aiming to invest in high-growth businesses founded by refugees. The fund plans to increase capital to £500,000 and deploy £50,000–£100,000 into three to five companies, establishing a track record for a planned £10 million fund. Research by TERN and Square shows refugee entrepreneurs contribute £520 million to the UK economy, with potential for £5.1 billion more. TERN established the fund with support from Atomico, and founding investors include Dominus, This Day Foundation, and Future Leaders. The fund targets software, AI, and climate tech startups with majority-refugee ownership, offering coaching and access to a network of 700+ refugee founders. Applications open October 14, 2026.
- The Refugee Venture Fund (RVF) launched with £300,000 initial capital, planning to increase to £500,000.
- RVF will invest £50,000–£100,000 in three to five refugee-founded companies.
- Research by TERN and Square estimates refugee entrepreneurs contribute £520 million to the UK economy.
- ·PR Newswire: Technology NewsProduct Launch
Abacum launches Modeler for agentic financial modeling
Abacum, an AI-native financial planning and analysis platform, has launched Modeler, an AI agent that enables finance teams to create business models using natural language or existing spreadsheets. Modeler transforms initial inputs into fully functional real-time models, building them in minutes instead of weeks. The agent selects structures from proven model plans, matches them with connected company data, and exposes the complete logic for review. It allows teams to describe a plan, upload an Excel file, approve variables, and trust the deterministic calculation engine. Modeler is available to all Abacum clients at no extra cost. The company has over 500 clients in 40+ countries and is backed by over $100 million in investments.
- Abacum launched Modeler, an AI agent for financial modeling.
- Modeler builds models in minutes from natural language or spreadsheets.
- Modeler is available to all Abacum clients at no extra cost.
- ·Tech.euAI Infrastructure
Callosum Raises $100M Seed Round for Multi-Chip AI Infrastructure
UK AI startup Callosum has raised $100 million in a seed round led by European VC Atomico, with significant participation from Plural, DCVC, and the UK's Sovereign AI, alongside angel investors. The company, founded by Cambridge neuroscientists, builds software infrastructure that allows AI workloads to run across different chips and AI models. Callosum challenges the industry's prevailing 'monoculture' belief that superintelligence will come from a single AI model running on identical chips. The startup argues that real-world problems are heterogeneous and require diverse computing capabilities. It also announced a partnership with US chip company Cerebras to integrate ultra-low-latency inference into its platform. Callosum previously raised $10.25 million in February 2026 when it came out of stealth.
- Callosum raised $100 million in a seed round led by Atomico.
- Plural, DCVC, and Sovereign AI participated in the round, along with angel investors.
- Callosum previously raised $10.25 million in February 2026 when it exited stealth.
Vitruvian Partners
Recent Signals
- ·techcrunchFunding
Angle Health raises $600M at $2.7B valuation
Health insurance startup Angle Health announced a $200 million Series C round and a $400 million tender offer, giving the company a $2.7 billion valuation. The round was led by Vitruvian Partners with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator. The tender offer permits employees to cash out shares, and the transaction is expected to close later this month. Angle Health, a Winter 2020 Y Combinator alum, helps small businesses manage level-funded health plans, offering a middle ground between fully insured and self-funded options. The company's AI-powered platform integrates with payroll and HR systems, serves over 5,000 businesses, and is reportedly profitable. This funding round is notable as it comes from a non-AI-agent startup founded in 2019.
- Angle Health raised a $200 million Series C round.
- The funding round included a $400 million tender offer.
- The company's valuation is now $2.7 billion.
- ·AdweekAgentic Advertising
DeepIntent launches agentic ad platform Cora for pharma marketing
DeepIntent, a healthcare-focused adtech firm, has launched Cora, an AI-powered agentic advertising platform designed for pharmaceutical marketers. The platform uses multiple AI agents to handle campaign planning, audience strategy, and media execution, including linear TV via a VideoAmp integration. Cora aims to speed up marketing workflows, with beta tests showing a 50% reduction in planning cycles and over 95% of clients reporting faster processes. This launch follows DeepIntent's majority stake sale to Vitruvian Partners, which provided $637 million to develop AI tools. The company targets the growing complexity of pharma marketing, especially for niche drugs targeting small patient populations. Cora is also powered by Helix, a data application providing aggregated healthcare data, including payer signals and drug coverage insights.
- DeepIntent launched Cora, an agentic ad platform for pharma marketing.
- Cora uses AI agents for campaign planning, audience targeting, and execution.
- Cora integrates with VideoAmp for linear TV campaign execution.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Atomico and Vitruvian Partners share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks